A Phase 4 interventional study of Triamcinolone Hexacetonide 20 MG/ML in Juvenile Idiopathic Arthritis, sponsored by Oslo University Hospital. Completed at 5 sites in Norway. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2025-02-17.
Sponsored by Oslo University Hospital · Phase 4, Interventional, and Treatment
Inhibitors of tumour necrosis factor (TNFa) reduce inflammation in patients with juvenile idiopathic arthritis (JIA), but only 20-40 percent achieve a state of no or very little disease activity. Tailored glucocorticoid joint injections are widely used (usually in general anaesthesia), but no controlled studies have addressed the effect of this approach. In Norway there are unique possibilities for early interventions, rapid escalation of medication and individualised therapy. The investigators aim to find the optimal ways to increase disease control and improve quality of life for JIA patients.
The hypothesis is that JIA patients starting TNF-inhibitors with added steroid injection of inflamed joints, will lead to improved outcomes compared to TNF-inhibitors with no joint injections, and that therapeutic drug monitoring, modern imaging and biologic and clinical profiling can be utilised to characterise JIA patients with different anti-TNF responses.
MyJIA is a national investigator initiated 48 weeks RCT of JIA patients starting TNF-inhibitors; 202 JIA patients will be randomised at baseline to A) concomitant intra-articular glucocorticoid injections versus B) no injections. Primary endpoint is the rate of sustained remission from weeks 24 to 36. Possible risk factors for not reaching remission will be analysed including clinical characteristics, drug antibodies/serum concentrations, patients' reported health status and preferences, molecular signalling (based on transcriptional, cellular and genetic risk) and synovitis detected by modern imaging (ultrasound and whole-body MRI).
Patients will be recruited from all Norwegian health regions through an established collaboration. Unit of Paediatric Rheumatology, Oslo University Hospital, with an extensive research track in this field, will be the coordinating centre. Broad research cooperation across disciplines is established. The trial is highly innovative in evaluating treatment options and strategies to individualise and optimise the efficacy and safety of JIA treatment.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's enrollment of 189 is above the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Oslo University Hospital is the lead sponsor of 810 studies on the registry; 148 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Medical Conditions
Major comorbidity including uncontrolled infectious, neurological or mental disease, malignant disease, severe heart failure, severe renal failure, active ulcus ventriculi, and uncontrolled diabetes mellitus.
Prior/Concomitant Therapy
Corticosteroid use (including i.a. injection) less than 4 weeks prior to randomisation.
Other Exclusions
Intra-articular corticosteroid injections into active joints
Drug: Triamcinolone Hexacetonide 20 MG/ML
No intra-articular injections
JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints
Also known as: Lederspan
The proportion of JIA participants with sustained inactive disease
The proportion of participants with sustained, inactive disease from week 24 to week 36. Inactive disease is defined according the 2011 Wallace criteria: * No active arthritis† * Physician global assessment of disease activity score normal (0) * Erythrocyte sedimentation rate (ESR) within normal range * Morning stiffness ≤ 15 minutes * No active uveitis * No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA In addition, no use of any i.a. or p.o. corticosteroids from week 20 to week 36. †Active arthritis according to the ACR definition: 1. a joint with swelling not due to bony enlargement OR, if no swelling is present 2. limitation of motion accompanied by either pain on motion and/or tenderness.
Time frame: Week 24 to week 36.
The proportion of participants with ACR pedi 30% response
American College of Rheumatology (ACR) paediatric 30% response (30% improvement in a minimum of 3 of any 6 variables in the paediatric core set criteria with no more than one of the remaining variables worsening more than 30%). Pediatric core set criteria: * Physician's global assessment of disease activity (visual analogue scale (VAS), range 0-100 where 0 represents best possible outcome). * Patient's/parent's global assessment of overall well-being (VAS, range from 0-100 where 0 represents best possible outcome) * Functional ability (Childhood Health Assessment Questionnaire, CHAQ, lower scores are indicative of better functioning) * Number of joints with active arthritis (range 0-71 where 0 represents best possible outcome) * Number of joints with limited range of movement (range 0-70 where 0 represents best possible outcome) * Erythrocyte sedimentation rate (normalised to a 0-10 scale where 0 represents best possible outcome)
Time frame: Baseline to week 6,12 and 24
The proportion of participants with ACR pedi 50,70 and 90% response
American College of Rheumatology (ACR) paediatric 50, 70 and 90% response (50,70 and 90% improvement in a minimum of 3 of any 6 variables in the pediatric core set (see above) criteria.
Time frame: Baseline to week 6, 12 and 24.
Juvenile arthritis disease activity score (JADAS)
The JADAS is a composite measure of disease activity with a range from 0 to 101 where 0 represents the best possible outcome and 101 the worst possible outcome. The JADAS is calculated as a sum of scores from: * Physician's global assessment of disease activity (visual analogue scale ranging from 0-100 where 0 represents best possible outcome and and 100 the worst possible outcome). * Patient's/parent's global assessment of overall well-being (visual analogue scale ranging from 0-100 where 0 represents best possible outcome and and 100 the worst possible outcome) - Erythrocyte sedimentation rate (ESR) (normalized to a 0-10 scale, according to the following formula: (ESR (mm/hour)-20)/10. 0 represents best possible outcome and and 10 the worst possible outcome) * Number of joints with active arthritis (range from 0 to 71 where 0 represents best possible outcome and and 71 the worst possible outcome)
Time frame: Baseline to week 6, 12 and 24.
Time to inactive disease
Time (months) until participants reach inactive disease according to the Wallace criteria and JADAS.
Time frame: Baseline to 48 weeks
Proportion of Participants with Minimal Disease Activity
Proportion of Participants with Minimal Disease Activity
Time frame: Week 26 to 48
Change from baseline in arthritis-related pain severity as measured by pain VAS item
Change from Baseline in Arthritis-Related Pain Severity as Measured by Pain Visual Analog Scale (VAS). The Pain VAS ranges from 0 to 100 where 0 represents no pain and 100 the worst possible level of pain.
Time frame: 48 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oslo University Hospital